Navigation Links
Researchers find new hope for treatment of chronic leukemia
Date:8/17/2011

Wednesday, August 17, 2011, Cleveland: While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.

This information was released in the online edition of Blood, a weekly medical journal published by the American Society of Hematology.

Chronic lymphocytic leukemia (CLL), a cancer of the white blood cells that is incurable with standard treatment, is the most common type of leukemia in the Western Hemisphere. Conventional chemotherapy is effective at controlling CLL for many years, but the disease always relapses. CLL is characterized by an uncontrolled cell growth and division due to a defect in a process called programmed cell death, or apoptosis. A group of proteins called the Bcl-2 family is responsible for this defect.

Alex Almasan, Ph.D., a researcher in the Lerner Research Institute (LRI) of Cleveland Clinic in close collaboration with other researchers in both LRI and the Taussig Cancer Institute of Cleveland Clinic collected blood samples from patients with CLL and tested the ability of a new drug to kill the cancerous cells. The drug, Navitoclax, is already in early stage clinical testing for patients with CLL. Navitoclax appears to be effective for some patients, and until this research study, there had been no clear way to predict who will respond to its effects.

In addition, these studies can be informative to the currently ongoing clinical trials with Navitoclax in other hematologic malignancies or solid tumors.

"Follow-up studies on patients that have been treated with Navitoclax, particularly those that are poor responders, could determine whether the Bcl-2 family genes examined in this study may also be important for development of resistance to this agent," said Almasan.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers find way to align gold nanorods on a large scale
2. UBC researchers discover key mechanism that regulates shape and growth of plants
3. Researchers discover oldest evidence of nails in modern primates
4. Researchers map pathway of infection for a common, potentially life-threatening respiratory virus
5. Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors
6. Researchers discover freshwater mussel species thought to be extinct
7. NYU Langone researchers identify a signaling pathway as possible target for cancer treatment
8. Toronto researchers first to discover new genetic clue in the development of rheumatoid arthritis
9. Researchers decode workings of mysterious, but critical TB drug
10. Researchers fight cholera with computer forecasting
11. Vanderbilt researchers, international team, uncover genes linked to multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced ... "Digital Life Alliance" established by iCarbonX, the ... to build a "Global Digital Health Ecosystem that ... a combination of individual,s biological, behavioral and psychological ... agreement between the companies, SomaLogic will provide proteomics ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it ... and genetic testing lab equipment from two different leading institutes. This highly specialized laboratory ... of the United States. This 1-day online auction will take place on BidMed’s ...
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
Breaking Biology Technology: